| Filed On | Filing |
|---|---|
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 16 Nov 2026 | SCHEDULE 13G/A |
| 05 Nov 2026 | 10-Q |
| 22 Oct 2026 | 25-NSE |
| 13 Oct 2026 |
8-K: Other Events
Fast Track designation recognizes the potential of SAB-142 to address an unmet medical need for people with Stage 3 type 1 diabetes |
| 18 Sep 2026 |
Form 4: Kropotova Alexandra, CHIEF MEDICAL OFFICER
Gave up 473 shares to cover exercise price or tax |
| 21 Aug 2026 | 424B3 |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 14 Aug 2026 | SCHEDULE 13G/A |
| 12 Aug 2026 | SCHEDULE 13G |
| 10 Aug 2026 | SCHEDULE 13D/A |
| 06 Aug 2026 | 10-Q |
| 07 Jul 2026 |
8-K: Regulation FD Disclosure
MIAMI, July 7, 2026 – Breakthrough T1D, the leading global type 1 diabetes (T1D) research and advocacy organization and SAB Biotherapeutics, Inc. (Nasdaq: SABS), a clinical-stage biopharmaceutical company developing a fully human anti-th... |
| 26 Jun 2026 |
Form 4: Kropotova Alexandra, CHIEF MEDICAL OFFICER
Gave up 988 shares to cover exercise price or tax |
| 18 Jun 2026 |
8-K: Submission of Matters to a Vote of Security Holders
On June 18, 2026, SAB Biotherapeutics, Inc. (the “Company” or “SAB”), held its 2026 Annual Meeting of Stockholders (the “Annual Meeting”). The total number of shares of common stock entitled to vote at the Annual Meeting was 77,966,409, ... |
Loading...